ELOVL3 and Alzheimer disease: In non-lesional atopic eczema, the compensatory mechanism involving ELOVL3 appears to be sufficient, in contrast to AD lesions, where neither palmitic acid nor stearic acid increases can be blocked [14], suggesting partial or limited compensation.